initi outperform continu growth
optron segment
initi target price initi coverag nitto denko
outperform rate target price potenti return rate
premis three main factor strong earn momentum
continu sale profit growth optron industri tape
segment continu improv earn power behind
success launch new product
optron pois sustain profit growth op forecast
yoy growth respect optron
busi pois continu top-lin growth center ito iridium tin
oxid film owe upturn valu nitto denko compon use per
handset high-end smartphon expect profit recov sharpli
smartphon maker begin advanc product new high-end
model compani industri tape contribut improv product
effici client busi also continu see top-lin growth
even barrier entri remain rel high also look earn
improv launch new product life scienc segment
nucleic acid medicin contract manufactur drug discoveri busi still
posit growth field medium term expect wane
follow cancel certain contract develop project
forese futur segment unlik meaning impact
result
announc profit set recov brisk product
high-end smartphon risk includ declin optron compon per
handset due design chang high-end smartphon client sluggish sale
major high-end smartphon client yen appreci versu dollar
indic
valuat target price deriv fair price-to-earnings
ep fair price-to-earnings refer averag
novemb expect nucleic acid drug rose
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
issuanc retir stock
net chang cash
number share mn
figur medium-term target sale growth
relat car electron
figur op estim segment
charl martineau univers toronto tabl content
invest opinion valuat
initi outperform target price
compani histori manag strategi
busi structur focu
expect continu profit growth smartphone-rel busi
smartphon market shift high-end
ito film smartphon key growth driver
priorit margin tv-use polar
improv margin print circuit materi process materi stabl
signific medium-term growth potenti car electron electron
steadi sale growth possibl function base
transport field manag
earn stall growth like long run
forecast double-digit profit growth medium-term target look
product nucleic acid bulk pharmaceut
invest opinion valuat
initi outperform target price
attract valuat given favor prospect profit growth
target price deriv fair price-to-earnings ep estim
fair price-to-earnings refer averag novemb
expect nucleic acid drug rose
nitto denko share price ralli novemb buoy expect earn
growth stock subsequ correct due cancel certain
contract nucleic acid medicin develop project optron segment
emerg concern inventori pressur high-end smartphon share ralli
somewhat april expect event catalyst follow result
brief rebound lack strength
think howev valuat attract see ampl upsid share due
three key factor expect optron profit recov sharpli
driven advanc product new high-end smartphon increas nitto
denko sale per handset forecast continu sale profit growth highli
competit industri tape segment expect continu improv
compani overal earn power behind success launch new product
forecast yoy op growth
tape segment
pois
digit op growth
expect nucleic acid drug
expect rise
nitto denko
handset high-end
smartphon
smartphone-rel busi expans drive optron segment
optron segment record op growth yoy rise sale
drive overal earn strong perform result rebound
correct smartphon product coupl increas industrywid high-
end smartphon volum size smartphon display upturn nitto denko
compon valu per handset aris shift major smartphon maker
look rise nitto denko compon valu per handset
free-form lcd edge-to-edg display cut-out notch top
new model major smartphon maker expect ito film key top-lin
driver amid increas phone out-cel touch panel ito film sale rose yoy
expect growth linger impact product
correct off-set launch new model drive sale
profit growth see sale growth ito film key profit driver specif
new model remain unclear point assum free-
form lcd screen model replac exist model toward note
factor entir new busi major smartphon maker
industri tape segment also pois continu profit growth
view industri tape segment pois continu growth steadi
prolifer car electron propel automot electrif autom
segment handl rang industri process materi combin variou
manufactur process help client bolster product expect busi
continu benefit rel high barrier entri continu see stabl
top-lin growth look success launch new product focus shift
toward higher-margin product lead steadi improv segment earn power
near-term expect life scienc segment wane still long-
steadi increas clinic test nucleic acid look steadi growth
longer term contract manufactur busi area nitto denko
command high market share howev expect temporari downturn sale
follow cancel contract develop project major client
think pace profit growth rel slow due up-front develop
cost nucleic acid drug discoveri busi busi like red
exclud payment receiv relat develop project cancel
note expect move modest profit
potenti catalyst includ clear sign company-wid profit growth quarterli result
margin improv industri tape segment
risk includ declin optron compon per handset due design chang
high-end smartphon client sluggish sale major high-end smartphon client
model declin op everi shortfal major high-end smartphon product
volum forecast guidanc premis annual op pull
lower one yen appreci versu dollar
high barrier entri
improv
profit
launch new product
limit impact
earn
chang impact
compani histori manag strategi
technolog develop sanshin activ drive top-lin
nitto denko found domest product electr insul
materi includ synthet varnish electr insul cloth nitto denko core
technolog includ polym coat technolog part compani focu
earli day coupl adhes polym analysi evalu expertis
cultiv tape-rel busi nitto denko product develop capabl
cornerston strength compani
nitto denko sanshin three new activ program strategi creat new
demand develop new product seek new applic
possibl compani consist achiev earn growth owe focu
expand product rang nitto denko achiev record sale op
nitto denko pursu global nich top strategi focus leverag
compani competit edg technolog develop product command high
market share recent compani also pursu area nich top strategi
aim develop product gear geograph area specif need thu
captur top market share area aim subsequ captur global
market share initi help nitto denko steadili bolster earn
power stave commodit
found
core technolog
commodit
favor creat high-
dispers mix
polym analysi evalu technolog
acoust vibrat characterist analysi
expand scale sale
busi structur focu optron
optron account sale op
nitto denko core busi optron mainli involv product
display materi segment account companywid op segment
oper margin opm rel high
figur nitto denko sale segment
figur nitto denko op segment
sale op
expect continu profit growth
smartphone-rel inform fine materi key variabl
chang smartphon display drive busi domain expans tv-relat
busi focus profit
core busi within optron segment inform fine materi account
roughli segment sale print circuit materi mainli fpc
hard disk drive account around sale process materi mainli
semiconductor-rel account remain
tv-relat product histor core busi segment manag
focus maintain profit busi model ensur steadi profit
oper line despit gradual declin sale smartphon display materi
largest impact earn momentum especi polar film ito film
oca optic clear adhes sheet busi enjoy steadi top-lin
growth particularli product high-end smartphon
polar film control level transpar within display allow light
specif characterist pass film lead improv imag qualiti nitto
denko make standard polar film special process film addit
function layer competitor nitto denko space includ sumitomo
chemic samsung sdi lgc high-end smartphon sumitomo chemic
also key competitor
ito film transpar conduct film coat iridium tin oxid allow light
electr signal pass accordingli work switch nitto denko
top market share particularli high share high-end smartphon rival includ
oik co teijin
optic clear adhes adhes tape superior transpar use
bond materi within display key characterist oca tape limit chang
appear even high-temperatur high-humid climat expos light
forecast yoy growth optron segment op
segment pois growth heel robust expans
optron segment record op growth yoy rise sale
drive overal earn strong perform brought rebound
correct smartphon product coupl upturn nitto denko
compon valu per handset shift major smartphon maker
estim op declin yoy due inventori adjust major
smartphon maker sale op rise sharpli full year due start
product new smartphon model
look rise nitto denko compon valu per handset new model
major smartphon maker particular note expect ito film key top-lin
focu
high-end
oca
optron op pois
recov sharpli
satur volum
term still grow
valu
smartphon market shift high-end model
smartphon asp like continu rise
global smartphon shipment flat yoy expand valu term
expect overal volum remain flat beyond due market satur
within see volum increas high-end model drive asp even higher
asia tech team forecast yoy declin smartphon shipment volum
look shipment valu increas asp rise
weight full hd
higher resolut
smartphon display increas resolut size
smartphon display see shift toward higher resolut full hd higher
resolut increas total shipment
screen sharper full hd made particular gain reflect
shift amorph silicon a-si low-temperatur polysilicon ltp design
also increas weight display accompani use iphon
increas function drove rebound asp small mid-size smartphon display
expect continu
rise asp smartphon display posit nitto denko
nitto denko especi strong high-value-ad display materi shift
higher resolut clear posit compani also benefit shift larger
screen size mean increas surfac area per phone product addit
anticip increas busi opportun accompani shift free-
form ltp display edge-to-edg display cut-out notch top
figur display unit shipment resolut
figur percentag resolut display unit
full hd wqhd
full hd wqhd
figur display unit shipment type
figur percentag type display unit shipment
figur display smartphon shipment trend
ito film smartphon key growth driver
chang display materi lead busi opportun
increas non-rectangl lcd model posit
on-going transform display technolog away tradit lcd screen
lead steadi rise valu nitto denko compon per handset look
model major smartphon manufactur estim shift in-cel
out-cel free-form lcd screen model result increas
tradit handset lcd screen use two nitto denko polar film
screen use polar film instead use ito film touch panel ito metal
film forc sensor touch oca film protect film free-form display requir
irregular-shap process lead higher unit price shift out-cel
touch panel necessit use ito film
ito film sale growth drive optron profit growth
forecast ito film sale growth growth
optron segment suffer yoy op declin due
product adjust major smartphon maker howev segment move back
profit growth high-end smartphon maker china began shift
toward model advanc featur segment post continu
profit growth owe new model major smartphon maker
upturn compon valu per handset howev segment op dip due
product adjust mainli model
impact product adjust linger expect
rebound overal sale inform fine materi major smartphon
maker begin advanc product model look top-lin growth ito film
drive profit also expect higher sale oca model polar film
mobil devic expect increas asp free-form lcd film look sale
declin slightli overal due weak convent lcd expect sale mid-size
panelus polar film trend flat
spec new model due beyond remain unclear would expect
free-form display model replac exist model model assum
plu free-form lcd screen ratio major smartphon maker
rise
robust product line-up give compani room off-set risk design
chang client
chang touch panel technolog risk increas adopt polar film
model potenti upsid driver
ito film use smartphon in-cel on-cel touch panel make
chang touch panel technolog high-end smartphon potenti risk howev
expect out-cel util non-rectangl lcd model lead higher
potenti upsid driver increas adopt nitto denko product
smartphon focus especi whether major smartphon maker use
antireflect film circular polar film model current
assum
compani benefit
rise asp
ito film oca
content shift
profit like mute
pois sharp
rebound
risk reduct
out-cel touch panel
high end
figur nitto denko busi domain expans driven chang display technolog major
note area nitto denko current busi domain
believ compani ito film metal film transpar adhes sheet oca protect film use model major smartphon maker model ito film
two polar use free-form lcd model
polar tv
polar non tv
polar tv
polar non tv
current much
swing factor
technolog sector asia feedback hardwar demand still soft japanes maker like rais mlcc price
priorit margin tv-use polar film
shift ultra-thin polar film leverag ip secur profit
tv-use polar film core earn pillar nitto denko
contract tv market downward pressur price increasingli stiff
competit nitto denko strategi busi nowaday maintain
profit specif strategi center three core initi roll-to-panel
system deliv packag servic panel maker client direct use within
client product process continu shift toward ultra-thin polar film
develop royalties-bas busi model via technolog licens
part roll-to-panel busi nitto denko suppli polar film larg roll
along adhes equip client instead suppli precut film nitto denko
engin support client process lead improv product
client ultra-thin polar film offer low shrinkag thu competit option
use high-end display cut panel client product site film enter
front-end product china accord compani plan nitto denko
employ three-prong product structur manufactur oper japan
korea china technolog licens nitto denko enter technolog
partnership china hangzhou jinjiang group large-scal polar film last
novemb partnership nitto denko assist hangzhou jinjiang
develop front-end polar film facil agreement includ
contract period five year specifi technolog support fee nitto denko
slate book product get underway
improv margin print circuit materi
withdraw convent fpc materi high margin hdd fpc
may nitto denko sold chines subsidiari handl it-rel fpc materi nok
nitto denko core focu area fpc materi hard disk drive expect
busi turn profit start remov money-los
chines subsidiari estim busi run annual oper loss
around product mix improv thank increas product high-
process materi busi mainli semiconductor-rel
busi mainli handl adhes tape semiconductor wafer process back
grind tape dice tape mold sealant film tape busi perform
tend move line semiconductor product trend busi stiff
competit hitachi chemic market leader earn growth quit
kept overal market growth overal busi becom
signific deterr overal earn momentum
guidanc
fall profit
high-margin new
sale op
signific medium-term growth potenti car
electron electron industri applic
forecast double-digit op growth on-going improv
industri tape segment split function base product busi
classif function base product busi divid structur
materi use final product process materi use product process
consum compani tape product use varieti applic
includ automobil electron industri sale tape depend amount
use product product process make volum base level
product activ sector
profit growth driven higher sale electron sector especi
smartphon compani strengthen earn structur reduc low-
margin product pivot new product higher margin nurtur
sanshin activ
later look margin improv would come double-digit
profit base potenti stronger sale structur materi process
materi transport busi especi car electron
base
steadi sale growth possibl function base
expect stabl growth structur materi process materi
approxim one-third sale function base product busi
electron field two-third field applic sale
structur materi process materi consum materi
base result sale field applic
structur materi relat smartphon double-sid tape foam
materi ventil materi process materi tailor product
process user creat high barrier entri materi help custom
self-driv could
improv product effici sale expand nitto denko aim improv
product mix pivot toward new product better margin
temish characterist product context fluoroplast porou film
million micropor per squar centimet temish waterproof dustproof
allow air pass product also featur excel water repel
heat resist chemic resist weather resist electr properti
lamin compound variou base materi commerci
ago sale temish grown sharpli past five year especi air
filter vacuum cleaner cleanroom etc sound pass membran
smartphon timepiec digit camera etc intern pressur adjustor
transport field manag focu
electron like propel growth
transport busi handl product automobil aircraft railway
ship automot product domin sale compani automot
product found vehicl includ exterior bodi interior engin
room ecu
look ahead see growth sale like driven car electron field
automot product alongsid advanc vehicl electrif autom car
electron current account around transport busi
estim insul materi motor use electr vehicl expect demand
strengthen oil-resist motor due increas use oil-cool motor
self-driv car expect stronger demand part materi use head
display hud millimeter-wav radar radar part materi includ low-
dielectr substrat enhanc detect rang antenna radio wave absorb
interfer prevent transpar heater visible-light-block materi
use hud
nitto denko target strong growth period medium-term plangrowth
believ achiev consid new product launch sinc margin higher
compani car electron product product anticip
improv product mix medium term
figur medium-term target sale growth relat car electron
sale op
earn stall growth like long
contract project halt nucleic acid drug contract
segment profit improv slowli weigh develop cost
nucleic acid drug discoveri
life scienc segment split long-stand medic tape busi
nucleic acid drug busi contract manufactur in-hous drug discoveri
approxim segment sale contract manufactur
nucleic acid drug also driver profit growth recent year
howev sale decreas due halt certain contract project
despit contractu agreement give nitto denko abil recoup lost sale
lump-sum payment owe halt project howev expect sale fall
sharpli yoy loss look like lump-sum payment exclud
onward forecast recoveri nucleic acid drug contract manufactur
sale anticip minor improv profit narrow loss
given risk custom could halt contract project
escal develop cost associ nucleic acid drug discoveri
still posit long-term growth driver
amid increas number clinic trial nucleic acid drug strong growth
potenti contract manufactur busi high market share
accord nitto denko materi compani involv earli stage
phase ii clinic trial phase trial four drug approv phase clinic
trial look like increas indic growth potenti compani contract
nucleic acid drug discoveri develop phase potenti mileston
incom long term
nucleic acid drug discoveri divid drug treat progress liver
fibrosi alreadi out-licens bristol-my squibb bm drug treat
pulmonari fibrosi fibrosi organ bm exclus right
option cancer treatment compani develop regard
nitto denko alreadi receiv one-tim payment novemb
stand receiv addit mileston one-tim payment depend clinic
progress regard compani intend out-licens drug
therebi rais expect mileston payment categori howev
clinic trial need time complet develop cost take preced
profit sale
stall
partner bm
fibrosi treatment
strength chemic
global share
nucleic acid drug
second antibodi drug nucleic acid drug next-gener drug
promis high specif efficaci
nucleic acid drug pharmaceut util nucleic acid build block dna
rna bond target area nucleic acid treat intract diseas
suppress undesir gene insid cell dna store genet inform
nucleu cell rna bind protein classifi three main type
mrna trna rrna messeng rna mrna play role messeng
convey genet inform dn transfer rna trna collect deliv amino
acid ribosom rna rrna link amino acid togeth form protein nucleic acid
drug mainli target mrna block convey genet inform therebi
inhibit function disease-caus cellular factor
nucleic acid drug produc use chemic synthesi process
regular chemic compar antibodi drug nucleic acid drug discov
shorter amount time lower cost howev drug readili broken insid
bodi make challeng deliv drug efficaci insid cell recent
year howev progress made make nucleic acid drug practic thank
develop drug deliveri system
one-stop servic strength nucleic acid drug contract
enter contract manufactur busi
long nitto denko involv product carrier polym
bead materi nucleic acid drug work develop nucleic acid
drug nitto denko mark entri busi contract
manufactur organ acquir nitto denko avecia
largest market share nucleic acid drug contract manufactur nitto
denko current global market share rival includ agil
one compani strength abil provid one-stop servic anoth
abil address broad rang need initi phase small-lot develop
commercial-scal product nitto denko avecia compani acquir irvin
pharmaceut servic provid drug analysi servic well avrio
charl martineau univers toronto biopharmaceut provid asept fill finish servic establish
nitto avecia pharma servic offer one-stop servic compani began
offer small-lot synthesi servic pharmaceut compani japan upon
clinic progress nitto denko avecia abl smoothli ramp product
figur acquisit relat nucleic acid drug contract manufactur
top share contract manufactur
nucleic acid medicin
contract manufactur nucleic
irvin pharmaceut servic analyt servic
enter contract manufactur nucleic acid
expans pipelin increas
expans analysi method develop
figur one-stop servic nucleic acid drug contract manufactur
rich manufactur experi antisens sirna
work evolv nucleic acid drugsmrna etc
agreement bm
drug phase ii
nucleic acid drug discoveri develop phase
wait clinic progress nash cirrhosi treatment
nitto denko reach exclus licens agreement bm
develop product sale drug advanc hepat fibrosi still
phase trial treatment target sirna therapi cut mrna new
therapi patient advanc non-alcohol steatohepat nash cirrhosi
bm current conduct phase trial drug candid receiv fast track
design us food drug administr fda base exclus
licens agreement nitto denko receiv one-tim payment
includ sale op clinic progress made nitto denko right
receiv one-tim payment nda file regulatori mileston royalti one-
time payment sale achiev sale mileston
charl martineau univers toronto pursu out-
hepat fibrosi
busi long
histori profit
compar low
contract give bm option exclus right pulmonari fibrosi fibrosi
organ option exercis would expect nitto denko receiv
mileston payment incom nitto denko current conduct phase trial
pulmonari fibrosi treatment us approxim patient
nash advanc nash liver cirrhosi liver cirrhosi
pharmacolog treatment approv yet
develop drug refractori cancer
fibrosi nitto denko develop drug kra mutat cancer
refractori cancer often seen lung cancer pancreat cancer colorect cancer
april compani gave present annual meet american
associ cancer research preclin efficaci new drug candid
compani intend advanc clinic trial aim out-licens
drug like fibrosi treatment
potenti mileston payment clinic progress take time
treatment nand cirrhosi pulmonari fibrosi phase trial said
drug candid advanc phase phase trial move
phase approv stage estim reflect mileston payment
medic tape busi expand product scope adhes
nitto denko launch medic tape busi began produc medic
adhes sheet appli adhes technolog accumul industri use
compani diversifi new product domain core product includ transderm
therapeut system product medic sanitari materi wound dress surgic
tape etc medic adhes tape sheet sport tape medic tape busi
posit stabl earn busi
long-term growth like transderm therapeut system product
primari maker transderm patch product
transderm patch deliv drug skin affect area nitto denko
began make transderm patch product commerci asthma
treatment high blood pressur treatment local anesthesia ischem cardiac
diseas treatment transderm patch differ oral administ inject drug
pain needl insert burden intern system
drug dosag control mitig side effect caus drug absorpt
although transderm patch subject drug price revis japan
profit appear rel stabl thank introduct new product
nitto passport system could expand type applic drug plan
current type drug deliv via transderm patch limit
fat solubl low-molecular drug use technolog altera therapeut
acquir nitto denko concentr develop nitto
passport system util activ transderm therapeut system tt technolog
broaden scope drug deliv skin
nitto passport make easi administ high-molecular drug includ
nucleic acid home also compat dosag manag system
see growth potenti product self-med field nitto denko aim
commerci collabor drug maker compani plan start
preclin test enter clinic test
charl martineau univers toronto expect profit
recov
target look achiev
estim op growth yoy
estim op total slightli higher guidanc
expect profit growth driven optron segment stronger sale ito film
also anticip brisk perform industri tape segment market
sector look margin continu improv growth high-value-ad
product life scienc segment forecast weaker sale profit nucleic acid
drug contract manufactur due custom halt trial estim life
scienc segment includ boost sale profit secur deposit paid
contract custom halt trial
forecast op yoy op look
profit hobbl weak optron caus product adjust
major smartphon maker also think investor alreadi brace lower
profit across high-end smartphone-rel name gener expect profit recov
sharpli product new smartphon get way think
carri high content nitto denko product
fx assumpt compani estim annual op
fx sensit neg appreci versu dollar
estim op growth yoy
estim op increas expect profit growth
driven optron industri tape segment forecast loss life
scienc segment one-tim profit drop pictur
estim op growth yoy
estim op expand think compani medium-term
target sale op attain
figur sale estim segment
figur op estim segment
nitto denko virtual zero debt cash posit roughli end-
compani solid financi posit gener free cash flow around
year
flow oper activ
flow invest activ
flow financ activ
focu next-
target sale op
aim creat new product key domain continu focu structur
nitto denko adjust three-year target medium-term plan everi year start
current fiscal year three-year plan period nitto denko
concentr manag resourc three prioriti domain next-gener
mobil electr vehicl self-driv car inform interfac smart devic
life scienc oligonucleotid therapeut focu creat new busi
believ long run domain could promot new core busi
compani target sale growth almost op
compar result
plan capital-expenditure
compani three-year budget invest broken
capital-expenditure manag fund company-wid spend includ
environment measur strateg spend amount
budget compani plan increas spend toward
final year plan plan
compani plan increas capital-expenditure
includ higher spend inform fine materi industri tape
industri fine materi plan call increas capac china larg lcd polar
film specif start front-end product give compani
integr capabl combin exist back-end facil increas
capac ito film amid boom demand capital-expenditure remain center inform
fine materi industri tape beyond
compani plan increas spend toward final year plan
plan
manag priorit alloc cash order capital-expenditure dividend
deal share buyback note compani plan invest heavili
expect dividend steadili increas given compani
earn growth potenti abil gener cash flow solid financi posit
januari nitto denko announc program buy back share
februari juli share outstand exclud treasuri
stock bought back may compani unlik
announc new share buyback near futur believ share buyback could
becom possibl medium-term target op begin
figur dividend pay-out ratio
announc januari
charl martineau univers toronto figur nitto denko sale op segment
sale segment
op segment
sale
sell gener administr expens
research develop
incom incom tax
cash equival
trade receiv
invest account use equiti method
trade payabl
total liabil equiti
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time also comprehens
metric tradit roe
nitto denko cfroi gener match exceed cost capit last fiscal
year settl level doubl specialti chemic peer japan
cfroi drive differ slightli higher margin
higher asset effici sale divid holt definit asset nitto denko cfroi
also among least volatil peer compani measur last five year
therefor demonstr high degre persist
figur aggreg cfroi profil japan specialti chemic industri
estim point higher margin driven ito film optron busi well
mix improv industri tape believ take ebitda margin
level offset improv fairli steadi growth balanc sheet
capit expenditur remain high least next three year
cash balanc continu grow collect point reduct
asset effici togeth forecast margin suggest cfroi averag
steadi next five year
charl martineau univers toronto scenario shown figur extent achiev margin also
maintain medium term holt valuat suggest healthi upsid
margin hold chang margin would chang valuat
state differ current share price would appear emb reduct
ebitda margin
sale growth parallel point chang forecast
cfroi discount rate
asset growth
credit suiss holt cfroi holtar trademark regist trademark credit suiss group ag affili unit state countri
charl martineau univers toronto product nucleic acid bulk pharmaceut
figur step product nucleic acid bulk pharmaceut
step
analog stick variou type food skewer
analog
remov food
item
short
end
suppli
dna
nucleu cell
made nucleic
nitto electr industri co ltd form ohsaki tokyo produc electr insul materi japan
head offic reloc ibaraki osaka
begin product black tape
begin product anticorros tape
produc first plastic tape japan
begin product electr insul cast mold product
open first oversea offic new york
begin product fluoroplast product nitoflon
begin product surfac protect vinyl sheet spv
begin product adhes tape packag paper
list common stock second section tokyo stock exchang osaka stock exchang
begin product frp electr insul product double-co adhes tape
begin product semiconductor encapsul materi
begin product medic adhes sheet
form nitto denko taiwan nitto denko first oversea manufactur base
begin product flexibl print circuit
begin product seal materi nitto eptseal
begin product polar film liquid crystal display
begin product high-polym separ membran reverse-osmosi membran ultrafiltr membran
begin product tape athlet rehabilitaion tape tape nitreat
begin product transderm drug deliveri patch
begin product reinforc vibrat damp materi nitohard
celebr anniversari chang name nitto denko corp
begin product retard film liquid crystal display nrf develop plant tissu cultur technolog tissue-cultur panax ginseng
begin product protect film paint surfac automobil
begin product print wire materi hdd use wireless suspens
begin product polar convers film
acquir inc
head offic reloc osaka grand front osaka
open global market center tokyo japan
charl martineau univers toronto figur nitto denko histori technolog innov
protect film
protect film polar
film
lcd
larg screen
nucleid acid
conform sheet el
cast
resin optic
resin bga
hdd head
compani mention price
compani mention see figur
